IRVINE, CA--(Marketwire - October 07, 2010) - AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that the Company's initial preclinical animal study conducted at a major university demonstrating the study group having a 95% less occurrence of arterial plaque compared to the control group was reported in the Preclinical Results section of the October 4, 2010 edition of "BioCentury Part II, Essential Surveillance for Biotech and Pharma." BioCentury, a leading industry publication, also reported that AtheroNova plans to submit an Investigational New Drug application (IND) for the Company's atherosclerotic plaque regression compound during the first quarter of 2011.
"As reported in BioCentury, we are proceeding with our plans to initiate the submission of an IND for our atherosclerotic plaque regression compounds during the first quarter of 2011," stated Thomas W. Gardner, CEO of AtheroNova. "We are very encouraged by the initial preclinical results and look forward to proceeding with our development program while preparing for Phase I human trials following the planned IND submission."
AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The company is in the final contracting stage for its second animal study at the Cedars-Sinai Division of Cardiology in conjunction with a major university to validate the findings of its initial study and prepare for human trials. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis.
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding commencement of the second animal trial, an Investigative New Drug Application and Phase I human trials, and the development of applications for AtheroNova's compounds. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.